Mucous Membrane Decontamination Market size was over USD 8.08 Billion in 2023 and is anticipated to exceed USD 52 Billion by the end of 2036, growing at over 15.4% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of mucous membrane decontamination is evaluated at USD 9.2 Billion. The growth of the market can be attributed to the higher prevalence of healthcare-associated infection in hospitals backed by the growing regulations of keeping hygiene in hospitals. According to the data published by the National Library of Medicine, it was noticed that nearly 1.7 million patients in hospital facilities get healthcare-associated infections (HCAIs) annually while around 98,000 of them die as a result of these infections, which is 1 in 17 patients across the globe.
The mucous membrane is the inner lining of particular organs that is often moist and found in the nose, stomach, mouth, and lungs. Mucous membrane decontamination is the procedure of decrement of the physiological flora along with pathogens. Furthermore, the global mucous membrane decontamination market is estimated to flourish on the back of a higher number of infections associated with wounds that require treatment to prevent severe symptoms where surgeries are mandated to treat the infectious wound. For instance, about 32% of surgical site infections were observed in patients in the year 2019. Additionally, the increasing inclination toward infection prevention and control is further projected to enlarge the market size over the forecast period. Hence, all these factors are expected to influence the growth of the market positively during the forecast period.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
15.4% |
|
Base Year Market Size (2023) |
USD 8.08 Billion |
|
Forecast Year Market Size (2036) |
USD 52 Billion |
|
Regional Scope |
|
The global mucous membrane decontamination market is segmented and analyzed for demand and supply by administration into injectable, oral and topical. Out of the three types of administration, the oral segment is estimated to gain the largest market share in the year 2036. The growth of the segment can be attributed to the convenience availability and medicines orally administered and suitable for treating various diseases to provide quick relief coupled with higher prescription by doctors. Data released by Frontiers in Pharmacology in 2021 demonstrated that nearly 84% of pharmaceutical products are consumed orally. Oral route of drug administration is common and had been practiced for centuries. It also provides tons of benefits such as, low complexity, non-invasiveness, convenient, easy to purchase, no need of prescription for several oral drugs, affordable, and others.
The global mucous membrane decontamination market is also segmented and analyzed for demand and supply by drug class into antibiotics, corticosteroids, anti-inflammatory drug, and monoclonal antibodies. Amongst these four segments, the monoclonal antibodies segment is expected to garner a significant share in the year 2036. Monoclonal antibodies are the synthetic proteins prepared in the laboratories that are used on the cancer cells to bind them. Monoclonal antibodies are useful in carrying radioactive substances toxins, and drugs to cancer cells. Hence, there utilization is associated with cancer treatment. For instance, in 2020, around 10 million people lost their life.
Our in-depth analysis of the global mucous membrane decontamination market includes the following segments:
|
By Drug Class |
|
|
By Product Type |
|
|
By Administration |
|
|
By Distribution Channel |
|
North America Market Forecast
The North American mucous membrane decontamination market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2036. The growth of the market can be attributed majorly to the higher prevalence of autoimmune diseases backed by the presence of a developed healthcare infrastructure and the growing inclination of people and clinicians toward the utilization of novel drugs. For instance, in 2017, approximately 22 million Americans were anticipated to have at least one autoimmune disease. The number is further set to rise exponentially over the forecast period. Additionally, rapid growth in the health expenditure in the region which is expected to increase the spending capacity of people on health care is further anticipated to enlarge the market size over the forecast period. As of 2020, the national health expenditure of the United States was estimated to be around USD 4 trillion.
Asia Pacific Market Forecast
Furthermore, the market is also expected to witness notable growth opportunities in the Asia Pacific region with a total market share during the forecast period. rising prevalence of skin infection such as moles, eczema, warts and fungal infection is estimated to propel the market growth over the forecast period. For instance, nearly 85% of the people aged between 30 to 60 are projected to be living with HPV infection, out of which, nearly 75% of them are Chinese and around 2% of them are Indians. Additionally, increasing prevalence or autoimmune disease coupled with rising instances of open surgeries in the region are also expected to boost the growth of the market over the forecast period.
Europe Market Forecast
Moreover, the mucous membrane decontamination market is projected to witness moderate growth opportunities in the Europe region by holding a share during the forecast period. Similar factors such as, escalating instances of skin infection and spike in the prevalence of autoimmune diseases are estimated to fuel the market growth during forecast period.
Astellas Pharma Inc. announced its global strategic collaboration with Sutro Biopharma, Inc. along with licensing agreement to improvise the development procedure of novel immunostimulatory antibody-drug conjugates shortly known as iADCs.
Sun Pharmaceutical Industries Limited and its entirely owned subsidiaries launched an oral drug, Bempedoic Acid, under the brand name Brillo in India which focuses on low-density lipoprotein cholesterol to be decreased.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?